drugset
drugset / Trial / NCT06025578

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578 ↗

Phase 3 Active not recruiting 1057 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Timeline

Start
2023-10-25
Primary completion
2027-12-27
Completion
2027-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Admilparant Small molecule — —

Indications

pulmonary fibrosis